Financial Information


ADDITIONAL FUNDING

Ideally, projects should have no existing funding. 

AUTHORIZED EXPENSES

Funding is contingent on a full review of the research budget. Budgets should include reasonable costs within the parameters below:

  • Research related study costs that are not standard of care (for clinical projects)
  • Funding for hours of work which are specified in the project
  • Supplies and consumables necessary to fulfil the project
  • Animal-related costs

UNAUTHORIZED EXPENSES

  • Salaries beyond recipient’s grant for their direct project work
  • Fringe benefits
  • Travel or housing related to sabbaticals
  • Fees for tuition
  • Membership dues, congress/meeting registrations, subscriptions, books, or journals
  • Travel costs to present data
  • Publication costs

DISBURSEMENT OF FUNDS

Projects will receive funding based on project-related milestones, including receipt of scheduled progress reports. Additional information related to the timing of payments will be outlined in the research agreement. 

FUNDS AND FINANCIAL REPORTS

Funding provided through the CF RIA program may be subject to reporting under applicable transparency laws and codes. 

A final financial report is due 60 days after the end of the funding period reconciling the proposed budget with the actual expenditures. In the event that unexpended funds remain at the end of the funding period, these funds must be returned to the CF RIA program.

PrivacyTerms of Use
© 2017 Vertex Pharmaceuticals Incorporated | VXMA-HQ-92-00065 | 10/2017
Vertex and the Vertex triangle logo are trademarks of Vertex Pharmaceuticals Incorporated
CF RIA program funding is supported by Vertex Pharmaceuticals Incorporated